Crossmark

The efficacy and safety of relatlimab/nivolumab combination therapy in patients with advanced melanoma: a systematic review

Crossref DOI link: https://doi.org/10.1007/s00403-024-03579-9

Published Online: 2024-12-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hasanzadeh, Saba https://orcid.org/0009-0005-0121-0610
Farokh, Parisa https://orcid.org/0000-0002-8135-9474
Vazifeh, Fatemeh https://orcid.org/0009-0007-5176-6259
Hosseini, Golsa sadat https://orcid.org/0000-0003-3014-7575
Rezaei, Leila https://orcid.org/0009-0006-6807-2950
Ghaedrahmati, Mozhgan https://orcid.org/0009-0006-3846-3272
Razaghi, Zahra https://orcid.org/0000-0003-0039-9501
Rezaei Tavirani, Mostafa https://orcid.org/0000-0003-1767-7475
Robati, Reza M https://orcid.org/0000-0002-7947-8642
License Information

Text and Data Mining valid from 2024-12-05

Version of Record valid from 2024-12-05
More Information

Article History

Received: 7 October 2024

Revised: 7 October 2024

Accepted: 26 November 2024

First Online: 5 December 2024

Declarations

:

: The authors declare no competing interests.

: The authors declare that they have no conflict of interest.